Role of DaTSCAN and clinical diagnosis in Parkinson disease

Neurology

Volumn 78, Issue 10, 2012, Pages 696-701

  De La Fuente Fernández, Raúl ^a  

^a Universidad de La Coruña   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IOFLUPANE I 123;

ARTICLE; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; NEUROIMAGING; NEUROPATHOLOGY; PARKINSON DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

EID: 84860800663     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318248e520     Document Type: Article

References (25)

1. Dauer W, Przedborski S. Parkinson's disease: Mechanisms and models. Neuron 2003;39:889-909. (Pubitemid 37130207)
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
3. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-870. (Pubitemid 34279780)
4. Walker Z, Jaros E, Walker RW, et al. Dementia with Lewy bodies: A comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 2007;78:1176-1181. (Pubitemid 350057277)
5. US FDA. PCNS Advisory Committee Briefing Document. Available at: Http://www.fda.gov/downloads/AdvisoryCommittees/UCM176192.pdf. Accessed May 16, 2011.
6. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525-535. (Pubitemid 44262284)
7. GE Healthcare press release. Available at: Http://md.gehealthcare.com/ component/content/article/940-pressrelease/102-impact-of-datscan.html. Accessed May 16, 2011.
8. Parkinson's Disease (PD) Overview. National Parkinson Foundation. Available at: Http://www.parkinson.org/parkinson-s-disease.aspx. Accessed May 16, 2011.
9. US FDA. Available at: Http://www.fda.gov/downloads/Drugs/ InformationOnDrugs/UCM244361.pdf. Accessed May 16, 2011.
10. Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group. Mov Disord 2000;15:503-510. (Pubitemid 30333223)
11. Marshall VL, Reininger CB, Marquardt M, et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 2009;24:500-508.
12. Altman DG, Machin D, Bryant TN, Gardner MJ. Statistics with Confidence, 2nd ed.: BMJ Books. Bristol: JW Arrowsmith Ltd; 2000.
13. Eerola J, Tienari PJ, Kaakkola S, Nikkinen P, Launes J. How useful is [123I]beta-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry 2005;76:1211-1216. (Pubitemid 41208370)
14. Tolosa E, Borght TV, Moreno E; DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group. Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord 2007;22: 2346-2351. (Pubitemid 351155979)
15. Brenner DJ, Hall EJ. Computed tomography: An increasing source of radiation exposure. N Engl J Med 2007;357: 2277-2284. (Pubitemid 350190758)
16. Sodickson A, Baeyens PF, Andriole KP, et al. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology 2009;251:175-184.
17. Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography ex-aminations and the associated lifetime attributable risk of cancer. Arch Intern Med 2009;169:2078-2086.
18. Eckert T, Feigin A, Lewis DE, Dhawan V, Frucht S, Eidelberg D. Regional metabolic changes in parkinsonian patients with normal dopaminergic imaging. Mov Disord 2007;22:167-173. (Pubitemid 46374756)
19. Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 2007;22:2210-2215.
20. Jeon BS, Jeong JM, Park SS, et al. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 1998;43:792-800. (Pubitemid 28280223)
21. de la Fuente-Fernández R, Furtado S, Guttman M, et al. VMAT2 binding is elevated in dopa-responsive dystonia: Visualizing empty vesicles by PET. Synapse 2003;49:20-28. (Pubitemid 36618247)
22. Kupsch A, Bajaj N, Weiland F, et al. Changes in clinical management following DaTscan (ioflupane) imaging in patients with a clinically uncertain parkinsonian syndrome: Interim report: Poster session IV: Poster discussion session. 63rd AAN annual meeting, Honolulu, Hawaii, April 13, 2011. Details available at: Http://www.molecularimaging.net/index.php?option-com- articles&view-article&id-27260:aanioflupane-spect-imaging-can-diagnose- parkinsons-disease. Accessed May 16, 2011.
23. Benaderette S, Fregonara PZ, Apartis E, et al. Psychogenic parkinsonism: A combination of clinical, electrophysiological, and [(123)I]-FP-CIT SPECT scan explorations improves diagnostic accuracy. Mov Disord 2006;21: 310-317.
24. Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 2006;21:510-514.
25. Mateos JJ, Lomena F, Parellada E, et al. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology 2007; 191:805-811. (Pubitemid 46355894)